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Background: Mutations in SACS, leading to autosomal-recessive spastic ataxia of Charlevoix-Saguenay (ARSACS),
have been identified as a frequent cause of recessive early-onset ataxia around the world. Here we aimed to
enlarge the spectrum of SACS mutations outside Quebec, to establish the pathogenicity of novel variants, and to
expand the clinical and imaging phenotype.
Methods: Sequencing of SACS in 22 patients with unexplained early-onset ataxia, assessment of novel SACS variants
in 3.500 European control chromosomes and extensive phenotypic investigations of all SACS carriers.
Results: We identified 11 index patients harbouring 17 novel SACS variants. 9/11 patients harboured two variants of at
least probable pathogenicity which were not observed in controls and, in case of missense mutations, were located in
highly conserved domains. These 9 patients accounted for at least 11% (9/83) in our series of unexplained early onset
ataxia subjects. While most patients (7/9) showed the classical ARSACS triad, the presenting phenotype reached from
pure neuropathy (leading to the initial diagnosis of Charcot-Marie-Tooth disease) in one subject to the absence of any
signs of neuropathy in another. In contrast to its name “spastic ataxia”, neither spasticity (absent in 2/9=22%) nor
extensor plantar response (absent in 3/9=33%) nor cerebellar ataxia (absent in 1/9=11%) were obligate features.
Autonomic features included urine urge incontinence and erectile dysfunction. Apart from the well-established MRI
finding of pontine hypointensities, all patients (100%) showed hyperintensities of the lateral pons merging into the
(thickened) middle cerebellar peduncles. In addition, 63% exhibited bilateral parietal cerebral atrophy, and 63% a short
circumscribed thinning of the posterior midbody of the corpus callosum. In 2 further patients with differences in
important clinical features, VUS class 3 variants (c.1373C>T [p.Thr458Ile] and c.2983 G>T [p.Val995Phe]) were identified.
These variants were, however, also observed in controls, thus questioning their pathogenic relevance.
Conclusions: We here demonstrate that each feature of the classical ARSACS triad (cerebellar ataxia, spasticity and
peripheral neuropathy) might be missing in ARSACS. Nevertheless, characteristic MRI features – which also extend to
supratentorial regions and involve the cerebral cortex – will help to establish the diagnosis in most cases.
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Autosomal-recessive spastic ataxia of Charlevoix-Sague-
nay (ARSACS) was for long regarded as a subtype of
early onset ataxia restricted to the Quebec region due to
founder mutations from a French ancestor. After cloning
of the responsible gene, SACS, it became evident that
ARSACS is not limited to Quebec, and more than 100
different pathogenic mutations have now been identified
worldwide [1]. Most ARSACS patients show a typical
triad of early-onset cerebellar ataxia, lower limb spas-
ticity and peripheral neuropathy. Together with char-
acteristic T2-hypointensities in the pons [2,3], these
phenotypic features help to identify ARSACS in patients
with unexplained ataxia. However, three mutation-
proven individuals with an unusual phenotype (lacking
either spasticity or peripheral neuropathy) have been de-
scribed so far [1,4,5], indicating that the classical triad
might not be the presenting feature in all ARSACS pa-
tients, and that ARSACS might be underdiagnosed in
patients with atypical phenotypes. Moreover, the pre-
sumed high frequency of allele carriers around the world
[6] suggests that many subjects will be identified in the
future with SACS variants of unknown significance, thus
warranting the identification of further phenotypic fea-
tures that help to establish the clinical diagnosis.
Here we aimed (i) to expand the spectrum of SACS
mutations outside Quebec and to establish the patho-
genicity of novel variants, (ii) to identify phenotypic
characteristics that are shared by most ARSACS patients
and that further help to identify ARSACS in patients
with unexplained ataxia, spasticity or neuropathy, and
(iii) to assess non-classical presenting phenotypes that
indicate additional disease groups, in which mutational
screening of SACS should be considered in the molecu-
lar genetic work-up.Methods
From 2005 until 2012 we recruited a consecutive series
of 172 index patients in the ataxia outpatient clinics of
the Departments of Neurology and Pediatric Neurology
at the University Clinic in Tübingen (Germany) with (i)
progressive degenerative ataxia with age of onset ≤30 -
years, (ii) absence of ataxia in the parental generation,
and (iii) genetic exclusion of common subtypes of dom-
inant ataxias (SCA 1, 2, 3, 6, 7, and 17). Mutations caus-
ing Friedreich-, POLG- and C10orf2 (PEO1/Twinkle)-ataxia
were screened in the whole cohort. A molecular diag-
nosis could not be established in 83/172 patients (48%).
22 of these 83 patients with unexplained ataxia were
screened for ARSACS by direct sequencing of the
SACS gene (for details, see Additional file 1). These 22
patients were selected for direct sequencing by 2 cri-
teria: (1) pyramidal tract signs to the lower extremityin addition to the degenerative ataxia (20/22 patients); or
(2) variant abnormalities including the SACS region
detected by preceding homozygosity mapping and/or
whole-exome sequencing approaches (2/22 patients). In
all index patients with only one heterozygous or appar-
ently homozygous SACS variants, macro-deletions were
excluded by MLPA (see Additional file 1 for details). Fol-
lowing earlier recommendations on variant classification
and reporting [7], the likelihood of pathogenicity of
novel sequence variants was graded according to a 5-
class-system: class 1 = not pathogenic; class 2 = variant
of uncertain clinical significance (VUS), likely not patho-
genic; class 3 = VUS, uncertain pathogenicity; class 4 =
VUS, likely pathogenic; class 5 = definitely pathogenic
[7]. Only patients harbouring two variants of class 3 or
higher are reported here (see Additional file 1 for details
on variant classes and assignment of variants). The fre-
quency of the identified SACS variants was determined
in 3.500 European control chromosomes from individ-
uals with unrelated phenotypes analyzed by exome se-
quencing (for methodological details, see [8]) in Munich,
Germany. In addition, the frequency was assessed in the
exome variant server (EVS) of the National Heart, Lung,
and Blood Institute GO Exome Sequencing Project
(Seattle, WA, USA; URL: evs.gs.washington.edu/EVS/)
with the corresponding nucleotide positions being ana-
lyzed in >8.000 European and >4.000 African American
alleles and in the Database of Single Nucleotide Poly-
morphisms (dbSNP; Bethesda: National Center for Bio-
technology Information, National Library of Medicine
[dbSNP Build ID: 137]; available from: http://www.ncbi.
nlm.nih.gov/SNP/). In-silico predictions of the pathogen-
icity of point mutations were performed using PolyPhen-2
[9], SIFT [10] and MutationTaster [11]. Cosegregation of
novel variants was confirmed in all families with a second
affected family member. Compound heterozygosity was
confirmed by segregation analysis where parental DNA
was available.
Each mutation carrier was clinically characterized
by a movement disorder specialist and investigated
by nerve conduction studies (NCS), motor evoked po-
tentials (MEP), standard funduscopy, and routine mag-
netic resonance imaging (MRI) including T1-, T2-,
diffusion-weighted images (DWI) and fluid attenuated
inversion recovery T2 (FLAIR) images. The presence
vs. absence of thinning of the corpus callosum and of
atrophy of the cerebellar and parietal cortex were
evaluated independently by two examiners (M.S.; B.B.),
and the inter-rater reliability was determined by Cohen’s
kappa coefficient. Its value was interpreted following
Landis and Koch [12]. In case of disagreement, the
more conservative assessment (i.e. the absence of thin-
ning and atrophy, respectively) was adopted for final
judgement.
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Genetic spectrum
In total, 19 different SACS variants were identified across
different exons (Figure 1). 17 out of 19 variants are
novel, 2 have already been identified earlier (p. Arg728*;
p.Gln1709*; [6]) (see Table 1). The identified variants
comprised 6 nonsense mutations, 5 missense mutations,
5 frameshift mutations, 5 in-frame deletions, and 1 in-
frame duplication. These variants were observed in 11
index patients. In three families with known parental
consanguinity, homozygous SACS variants were ob-
served (Table 1). Four index patients had a positive fa-
mily history with affected siblings. Cosegregation of the
respective variants was demonstrated in all of them.
No macro-deletion or duplications were identified by
MLPA.
Fourteen of the novel 17 variants were not observed in
controls and in the EVS (Table 1) and - in case of mis-
sense mutations -were evolutionary highly conserved
(for conservation score PhyloP, see Table 1; for align-
ment data, see Additional file 2, each only for mis-
sense mutations). Two SACS variants - p.Thr458Ile
and p.Val995Phe - were also observed in heterozygous
state in 3.500 control chromosomes (p.Thr458Ile: 14/
3.500=0.4%; p.Val995Phe: 11/3.500=0.3%), in dbSNP
(p.Thr458Ile: 0.3% ESP Cohort pop; rs61729954; p.
Val995Phe: 0.1% ESP Cohort pop; rs142967124) and in
the exome variant server (p.Thr458Ile: 0.33% European
alleles; p.Val995Phe: 0.24% European alleles) (see Table 1).
The p.Thr458Ile variant was predicted to be deleterious
by three different in silico software tools (PolyPhen-2,
SIFT, MutationTaster). It leads to a change of an evo-
lutionary highly conserved amino acid (PhyloP Score:
6.26) (Table 1 and Additional file 2). However, the
physico-chemical differences of the involved amino
acids are only moderate. This finding together with
their occurrence in the general population leads to theFigure 1 SACS mutations. Graphical overview of mutations found in this
deletions). Different mutation types are marked with different symbols: mis
downward orientation; deletions = triangles with upward orientation. Sequ
indicating the pathogenicity class: red = pathogenic, orange = likely patho
protein are highlighted in green. AA = amino acid; HGMD = Human Geneclassification as VUS class 3 (uncertain pathogenicity).
The p.Val995Phe variant is predicted to be deleterious
only by SIFT, and affects an evolutionary less conserved
amino acid (PhyloP Score: -0.2) (Table 1 and Additional
file 2), thus also leading to the classification as VUS
class 3. Due to the frequent observation of these two
variants in controls and their uncertain significance, the
two patients harbouring either one of these variants (pa-
tient #10: p.[Thr458Ile];[Thr458Ile]) or the combination
of them (patient #11: p.[Thr458Ile]; [Val995Phe]) were
analyzed separately from the other 9 patients with two
SACS variants of ≥ class 4.
One SACS variant – c.13538 G>A (p.Ser4513Asn) -
was not observed in controls, but was found in the EVS
(0.02%) and was only moderately conserved. This variant
was found in a patient with two additional SACS variants
(patient #6), namely c.11624 G>A (p.Arg3875His) and
c.1647_1658del (p. Leu549_Leu552del). Only these two
variants, but not the first variant, were considered to be
likely pathogenic (VUS class 4), since they were absent
in controls and the EVS and were highly evolutionary
conserved. Unfortunately, DNA of the parents was not
available for testing allele segregation.
In one index patient (patient #2), an autosomal-
dominant ataxia had initially been assumed, based on
the positive family history for a three-generation late-
onset (>30 years), slowly progressive, pure cerebellar
autosomal-dominant ataxia in her paternal relatives
(in a aunt, cousin, and grandfather; or pedigree see
Additional file 3). However, the father of the index
patient did not show any ataxia (examined at age 80 years
by M.S.) and the index patient herself showed a strikingly
different early-onset ataxia. To rule out a possible digenic
ataxia, also the following SCAs were excluded in the index
patient: SCA 8,10, 11, 14, 15, 27 and DRPLA. The affected
paternal aunt and cousin did not show any of the two
(clearly pathogenic) SACS variants that were observed inand other studies (Human Gene Mutation database, except gross
sense mutations = squares; insertions/duplications = triangles with
ence variations identified in this study are coloured, with the colour
genic, yellow = uncertain. Known protein domains of the sacsin
Mutation Database.
























Patients with 2 pathogenic or likely pathogenic SACS variants
#1 index c.9305_9306insT p.Leu3102Phefs*8 frame shift 10 0 - - NA NA NA yes Pathogenic
(class 5)
c.9305_9306insT p.Leu3102Phefs*8
#1 sister see above
#2 c.2182C>T p.Arg728* nonsense 9 0 - - ND NA NA no6 Pathogenic
(class 5)
c.13056delT p.Phe4352Leufs*11 frame shift 10 0 - - NA NA NA yes Pathogenic
(class 5)
#3 index c.3769G>T p.Gly1257* nonsense 10 0 - - ND NA NA yes Pathogenic
(class 5)
c. 8584A>T p.Lys2862* nonsense 10 0 - - ND NA NA yes Pathogenic
(class 5)
#3 sister see above
#4 index c.11542_11544del p.Ile3848del in-frame deletion 10 0 - - NA NA NA yes Likely pathogenic
(VUS class 4)
c.11542_11544del p.Ile3848del
#4 brother see above






10 0 - - NA NA NA yes Likely pathogenic
(VUS class 4)
#5 sister see above
#6 c.11624 G>A p.Arg3875His missense 10 0 - - 6.34 29 Deleterious yes Likely pathogenic
(VUS class 4)
c.1647_1658del p.Leu549_Leu552del In-frame deletion 8 0 - - NA NA NA yes Likely pathogenic
(VUS class 4)




3.43 46 Contradictory yes Uncertain
(VUS class 3)
#7 c.5544dupA p.Val1849Serfs*48 frame shift 10 0 - - NA NA NA yes Pathogenic
(class 5)
c.12603C>A p.Tyr4201* nonsense 10 0 - - ND NA NA yes Pathogenic
(class 5)
#8 c.7277 G>C p.Arg2426Pro missense 10 0 - - 5.69 103 Deleterious yes Likely pathogenic
(VUS class 4)






















Table 1 SACS mutations (Continued)
#9 c.4954C>T p.Gln1652* nonsense 10 0 - - ND NA NA yes Pathogenic
(class 5)
c.5125C>T p.Gln1709* nonsense 10 0 - - ND NA NA no6 Pathogenic
(class 5)
Patients with 2 SACS variants of uncertain clinical significance class 3 (VUS3)
#10 c.1373C>T p.Thr458Ile missense 8 14/3500 rs61729954 (0.3%
ESP Cohort pop;
3.1% AGI ASP pop)
0.33% (EA);
0.05% (AA)





p.Thr458Ile missense 8 14/3500 rs61729954 (0.3%
ESP Cohort pop;
3.1% AGI ASP pop)
0.33% (EA);
0.05% (AA)
6.26 89 Deleterious yes Uncertain
(VUS class 3)
c.2983 G>T p.Val995Phe missense 10 11/3500 rs142967124
(0.1% ESP Cohort pop)
0.24% (EA);
0.02% (AA)
−0.2 50 Contradictory yes Uncertain
(VUS class 3)
EA= European alleles; AA= African American alleles; NA = not applicable; ND = not determined; rs = reference single nucleotide polymorphism (SNP) identifier; VU = variant of uncertain clinical significance. 1
Nomenclature of sequence variants follows the recommendations by the Human Genome Variation Society (HGVS, http://www.hgvs.org/mutnomen/) and refers the cDNA sequence NM_014363.4. 2 PhyloP was used
as a conservation score as originally implemented by Pollard and colleagues. It allows the rating of nucleotides from “not conserved” (−14.1) to “highly conserved (6.4) [13]. 3 The Grantham distance was used to
evaluate physico-chemical differences of amino acids (0 = no physico-chemical differences; 215 = large differences) [14]. 4 In-silico predictions were performed u g PolyPhen-2 [9], SIFT [10] and MutationTaster [11] 5
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patients with 2 SACS variants of unknown significance
#10 p.[Thr458Ile];
[Thr458Ile]





















n.a.= not available; n.k., not known; y= years; m=male, f=female; ATR, Achilles Tendon Reflex; Bab=babinski sign right/left; SARA= Scale for the Assessment and
Rating of Ataxia (according to [15]).
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Table 3 Electrophysiology and MRI findings
family
No.































patients with 2 likely pathogenic SACS variants
#1 p.[Leu3102Phefs*8];
[Leu3102Phefs*8]







+, vermal + + + + + +
#2 p.[Arg728*];
[Phe4352Leufs*11]







+, pancerebellar + + + + + +
#3 p.[Gly1257*];
[Lys2862*]
Sur: no SNAP Rad: no
SNAP





+, pancerebellar + + + + + +
#4 p.[Ile3848del];
[Ile3848del]










+ + + + - +
#5 p.[Leu796Tyrfs*13];
[L3995dup]






























+, pancerebellar n.a. n.a. n.a. n.a. n.a. n.a.
#8 p.[Arg2426Pro];
[Tyr2975Phefs*29]
Sur: normal Tib: normal not done +, vermal - + + + - -
#9 p.[Gln1652*];
[Gln1709*]







+, pancerebellar - + + + + -
patients with 2 SACS variants of unknown significance
#10 p.[Thr458Ile];
[Thr458Ile]






+ - - - - +
#11 p.[Thr458Ile];
[Val995Phe]
Sur: red SNAP Rad:
red SNAP
Tib: red CMAP prolonged
UE+LE
+, pancerebellar - - - - + +
Sur=sural; rad= radial; Tib= tibial, Uln=ulnar; SNAP=sensory nerve action potential; SNCV=sensory nerve conduction velocity; CMAP=compound muscle action potential; MNCV=motor nerve conduction velocity;
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tary ataxias should be considered in pedigrees where the
ataxia features differ strongly between pedigree members,
e.g. early onset vs. late onset ataxia or multisystemic vs.
pure cerebellar degeneration.
Phenotypic spectrum of index patients with two ARSACS
variants of at least probable pathogenicity
78% (7/9) of the 9 index patients with at least two variants
of VUS class 4 (likely pathogenic [7]) or pathogenic muta-
tions showed the typical ARSACS phenotype of typical
early-onset triad of cerebellar ataxia, lower limb pyramidal
tract signs (spasticity and extensor plantar response in 6/7;
only spasticity in 1/7 [patient #9]) and peripheral neur-
opathy, which was of axonal-demyelinating sensorimotor
type in all (7/7) subjects (Table 2). 1/9 patients (patient
#4) showed no spasticity, extensor plantar response or
cerebellar ataxia, but marked axonal-demyelinating sen-
sorimotor neuropathy (leading to mild subclinical afferent
ataxia). The same was true for his likewise affected
brother. In turn, in another patient (patient #8), cerebellarD E
G H





Figure 2 Characteristic MRI findings in ARSACS. Axial FLAIR images of u
central pons representing the cortico-spinal tract (white arrows): Moreover,
hyperintensity of the lateral pons when merging into the middle cerebella
arrow head) in patient #1. Also on coronal T2 images (C) the bilateral hype
and parietal atrophy is shown for the same patient in axial FLAIR (D, E) and
mid-body of the corpus callosum on sagittal T2 images is shown for patienataxia was present, but electrophysiological evidence of
peripheral neuropathy absent. Neither did this patient
show spasticity or an extensor plantar response. Thus, nei-
ther spasticity (absent in 2/9=22%) nor extensor plantar
response (absent in 3/9=33%) nor cerebellar ataxia
(absent in 1/9=11%) are obligate features in ARSACS.
Urinary urge incontinence was present in 7/9 patients
(77%), combined with faecal urge incontinence in 1
patient; erectile dysfunction was present in 1/3 male
patients aged ≥16 years (33%) (Table 2). Standard fun-
duscopy (available from 6/9 patients) revealed increased
demarcation of retinal nerve fibres close to the optic disc
in 1/6 (17%) patients (patient #5). No patient reported
hearing loss (0%). MEPs (available from 8/9 patients)
were abnormal to the legs in all patients (not evoked in
7/8, prolonged central motor conduction time in 1/8)
and to the arms in 75% (prolonged central motor conduc-
tion time in all 6/8 patients), indicating that pyramidal
damage does not only affect lower but also upper extrem-
ities in ARSACS (Table 3). This was true also for patient




pper pons (A) and middle pons (B) show hypointense strips in the
on the level of the mid-pons (B), they reveal diffuse slight
r peduncles (stars) and thickened middle cerebellar peduncles (white
rintensity of the lateral pons can be seen (stars). Bilateral post-central
sagittal T2 (F) images (white arrows). Thinning of the posterior
t #5 (G) and patient #2 (H) (white arrows).
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veal subclinical pyramidal damage in ARSACS.
MRI (available from 8/9 patients) demonstrated ce-
rebellar atrophy with predominance of the superior
cerebellar vermis in 88% (7/8) (Table 3 and Figure 2).
Interestingly, the single patient who was lacking cerebellar
atrophy, did also not show any clinical signs of cerebellar
dysfunction (but only mild afferent ataxia) (patient #4).
His MRI did reveal, however, developmental asymmetry of
the cerebellar hemispheres (Figure 3). All patients (8/8,
100%) showed linear pontine T2-hypointensities, and, in
addition, also bilateral FLAIR-T2-hyperintensities of the
lateral pons when merging into the middle cerebellar
peduncles (MCP) as well as thickening of the MCP
(Figure 2). 75% (6/8) of the patients exhibited an
arachnoidal cyst in the posterior fossa, 63% (5/8) bilateral
parietal cerebral atrophy (Figure 2), and 63% (5/8) a short-
stretched thinning of the posterior mid-body of the corpus
callosum (Figure 2). While interrater reliability for rating
of cerebellar atrophy (Cohens’s kappa: 1) and parietal atro-
phy (Cohen’s kappa: 0.8) was very good, it was only mod-
erate for thinning of the posterior mid-body corpus
callosum (Cohen’s kappa: 0.6). The lower interrater reli-
ability with respect to the corpus callosum, however, does
not lead to a possible over-reporting of corpus callosum
abnormalities, but rather to a possible underestimation as
in case of disagreement the more conservative estimate
was adopted for final judgement.
Phenotype of patients with two SACS variants of
uncertain clinical significance class 3 (p.Thr458Ile and
p. Val995Phe)
Compared to the aforementioned ARSACS patients, the
patient with the homozygous mutation p.Thr458Ile had
a relatively late onset of ataxia at age 30 years, with ab-
sence of clinical and electrophysiological signs of pyram-
idal damage and neuropathy (no spasticity, no extensorA B
Figure 3 Developmental asymmetry of cerebellar hemispheres. Axial T
developmental asymmetry of the cerebellar hemispheres (long arrows) wit
common infratentorial signs of ARSACS: thickening of the middle cerebella
(best seen on axial FLAIR, arrows, C).plantar response, normal muscle tendon reflexes, normal
vibration sense, normal nerve conduction studies, nor-
mal MEPs). Funduscopy revealed no increased demar-
cation of retinal nerve fibres. Like in other ARSACS
patients, MRI revealed minor atrophy of the superior
cerebellar vermis, an arachnoid cyst, and a thinning of
the posterior mid-body of the corpus callosum (Figure 4).
However, in contrast to all aforementioned ARSACS
patients, no linear T2-hypointensities in the pons or
T2-hyperintensities of the lateral pons and thickening
of the MCP were observed. Interestingly, MRI revealed
herniation of the cerebellar tonsils, resembling Chiari
malformation type 1 (Figure 4). The patient being com-
pound heterozygous for the p.Thr458Ile and p.Val995Phe
variants showed an early-onset triad of cerebellar ataxia,
pyramidal tract signs (bilateral spasticity and extensor
plantar response) and peripheral sensorimotor neuro-
pathy. However, nerve conduction studies revealed
pure axonal damage without evidence for a demyelin-
ating component, in contrast to all other ARSACS pa-
tients with neuropathy. Moreover, atrophy was observed
not only of the cerebellar vermis and hemispheres (like in
the other ARSACS patients), but also of the pons. Al-
though thinning of the posterior mid-body of the corpus
callosum was present, neither linear T2-hypointensities in
the pons nor T2-hyperintensities of the lateral pons and
thickening of the MCP could be detected.
Discussion
In this study we identified 9 novel index patients with
two pathogenic or likely pathogenic SACS variants.
These patients were part of a consecutive series of
n=172 patients with early-onset ataxia. Thus, ARSACS
accounts for at least 5% (9/172) of early-onset ataxias -
which makes it the second most common ataxia after
Friedreich’s ataxia (29%; 50/172) in our series. SACS
mutations were responsible for at least 11% (9/83) ofC
1 (A) and coronal T2 (B) MRI images of patient #4 demonstrating
hout cerebellar atrophy. Apart from this finding, this patient shows the
r peduncles (arrow head, A) and linear hypointensities of the mid-pons
A B
Figure 4 Developmental posterior fossa malformation resembling Chiari type I in the Thr458Ile+ p.Thr458Ile patient. (A) Midsagittal T2
MRI demonstrates herniation of cerebellar tonsils, resembling Chiari malformation type 1 (arrow). Also note the atrophy of the superior cerebellar
vermis (arrow heads). (B) Para-midsagittal shows slight short-stretched thinning of the posterior mid-body of the corpus callosum (arrow).
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parable to recent studies observing relative frequencies
of 12% (in 232 cerebellar ataxia patients [1]) and 13%
(in 85 patients with at least 2 of the 3 cardinal features
of ARSACS [5]).
The majority of our ARSACS patients (78%) presented
with the classical early-onset triad of cerebellar ataxia,
lower limb pyramidal tract signs and axonal-demyelinat-
ing sensorimotor peripheral neuropathy, thus corroborat-
ing other recent ARSACS case series [5,6,16]. However,
one index patient and his likewise affected brother did not
show cerebellar ataxia or clinical pyramidal tract signs (no
spasticity, no extensor plantar response), and were thus
initially presumed to suffer from Charcot-Marie-Tooth
(CMT) Disease. This finding corroborates a recent finding
of two ARSACS siblings presenting with a CMT-like pic-
ture [17]. Importantly, however, in contrast to these previ-
ously reported siblings, our index patient and his brother
did not even show mild spasticity or cerebellar ataxia. This
suggests that SACS should be considered in both compli-
cated and uncomplicated CMT.
On the other side of the phenotypic spectrum – and
in sharp contrast to these CMT-like subjects – neur-
opathy might also be absent in ARSACS as indicated by
patient #8 who did not show clinical or electrophysio-
logical evidence of peripheral neuropathy. So far, only
one ARSACS individual has been reported without clin-
ical and electrophysiologic signs of peripheral neur-
opathy, suffering from a very late onset phenotype
(ataxia starting at age 40 years) [5]. Our finding demon-
strates that even in early-onset cases, neuropathy is not
an obligate feature of ARSACS. It might, however, de-
velop at later stages of the disease.
Interestingly, patient #8 did also show neither spasticity
nor extensor plantar response. So far, only two ARSACS
individuals without lower-limb spasticity were described
[4], but both displayed bilateral extensor plantar response,thus suggesting that pyramidal involvement might have
been likely masked by the severe neuropathy in these two
individuals [1]. Since neuropathy was absent in our index
patient, the lack of spasticity cannot simply be explained
by a masking neuropathy. Thus, taken together, in con-
trast to the name of this “spastic ataxia of Charlevoix-
Saguenay”, neither spasticity (absent in 2/9=22%) nor ex-
tensor plantar response (absent in 3/9=33%) nor cerebellar
ataxia (absent in 1/9=11%) are obligate features of this dis-
ease. Although pyramidal tract involvement is common in
ARSACS patients, as illustrated by the fact that all of our
patients had abnormal MEPs, it might be only subclinical
in some of them.
Increased demarcation of retinal nerve fibres is also
not an obligatory feature of ARSACS. It was exhibited
only by 1 (17%) of our patients. This finding is line with
other recent studies that observed this feature only 1 out
of 8 [5] or in none out of 12 ARSACS patients [16], re-
spectively. Taken together, these findings illustrate that
increased demarcation of retinal nerve fibres might be a
specific, but not obligatory finding in ARSACS [5], espe-
cially in non-Quebec ARSACS individuals [1]. While the
high frequency of urge incontinence (77%) might be due
to either autonomic dysfunction or pyramidal damage
[18] (or a combination of both), erectile dysfunction ob-
served in one out of three male patients aged ≥16 years
(33%) is clearly an indicator of autonomic dysfunction.
So far, erectile dysfunction has only been reported in
one ARSACS patient [19], but might be underdiagnosed.
Thus, patients with ARSACS should be actively investi-
gated for autonomic disturbances.
Our imaging findings extend the range of diagnostic
features that help to diagnose ARSACS in patients with
unexplained ataxia, spasticity or CMT. All patients with
two pathogenic SACS variants showed not only the well-
established linear pontine T2-hypointensities [2,3], but
also bilateral FLAIR-T2-hyperintensities of the lateral
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correlate of this finding, which corroborates and extends
recent findings from other groups [3,16,20], are probably
abnormally large transverse pontocerebellar fibres [16].
The frequent finding of an arachnoidal cyst in the
posterior fossa (75%) and of developmental cerebellar
hemispheric atrophy in one patient underlines the hy-
pothesis that disease processes in ARSACS are not only
of neurodegenerative, but also of neurodevelopmental
origin [16,18]. These findings might help to differentiate
ARSACS from many other recessive neuropathic ataxias,
since they are not found e.g. in Friedreich’s ataxia or
POLG-associated ataxia [21].
It was recently suggested that structural brain damage
in ARSACS is not limited to infratentorial regions [16].
Here we extend this notion, demonstrating for the first
time that it also involves the cerebral cortex: 63% of our
patients showed bilateral parietal cerebral atrophy. 63%
of our patients also showed a short-stretched thinning of
the posterior mid-body of the corpus callosum. Al-
though this frequency is lower than in a previous study
reporting a thin corpus callosum (TCC) in all patients
[16], this finding substantiates the notion that disease
processes in ARSACS also frequently involve key asso-
ciative fibre bundles [16]. Thus, ARSACS should be part
of the differential diagnosis in spastic ataxias with TCC,
like e.g. SPG11, SPG15 [22] or GBA2 [23].
We identified 17 novel SACS variants. Two of them –
p.Thr458Ile and p.Val995Phe - were also observed in
controls with a frequency of 0.4% or 0.3%, respectively.
This indicates that they will likely be identified by many
labs in the future, thus warranting a timely discussion
whether they should be reported as pathogenic or not.
The finding of a recessive mutation in a heterozygous
state in controls does not per se refute a possible patho-
genic role, in particular if the variant is common (as e.g.
demonstrated by the expanded allele of FXN [Friedreich’s
ataxia gene], which is observed with a heterozygous car-
rier rate of 1/60 to 1/90 in controls [24], or by the two fre-
quent, clearly pathogenic c.1399 G>A [p.Ala467Thr] and
c.2243 G>C [p.Trp748Ser] POLG mutations, which are
observed with a heterozygous carrier rate of up to 1% in
several European populations [25]). In particular, the p.
Thr458Ile SACS variant might be pathogenic, given the in
silico predictions, the high conservation index, and the
MRI findings of a TCC as well as of a neurodevelopmental
posterior fossa disorder consisting of an arachnoid cyst
and herniation of tonsils in the homozygous carrier. Yet,
for the time being, we here prefer not to claim any patho-
genic significance, in particular given the large phenotypic
differences compared to the other subjects with patho-
genic SACS mutations. These findings illustrate a problem
that is likely to occur frequently in the future: findings of
variants with unknown significance may be frequent inSACS sequencing, given the fact that is has now entered
clinical routine in many ataxia clinics. Thus, seemingly
“atypical ARSACS phenotypes” should be scrutinized with
particular caution and underlying SACS variants should
ideally be analyzed functionally, e.g. with their impact on
mitochondrial fission dynamics [26].Conclusions
In sum, we here demonstrate that each feature of the
classical ARSACS triad (cerebellar ataxia, spasticity, per-
ipheral neuropathy, Charlevoix-Saguenay origin) might
in fact be missing in patients with SACS mutations, so
the name might be misleading. Atypical presentations
may be found much more frequently in the future when
ARSACS genetics becomes a standard tool of ataxia
work-up by new sequencing techniques and ataxia panel
diagnostics. Nevertheless, characteristic MRI features –
which also extend to supratentorial regions - will help to
establish the diagnosis in most cases. Moreover, the elec-
trophysiological finding of a demyelinating component
of the sensorimotor peripheral neuropathy will help to
distinguish ARSACS from other common recessive
ataxias like Friedreich’s ataxia, POLG or AOA2, where
neuropathy is almost exclusively of axonal type [21,27].Additional files
Additional file 1: A) SACS sequencing. B) MLPA assay. C) Criteria for
classification of sequence variants.
Additional file 2: Alignment results. Multiple sequence alignments for
novel SACS missense mutations identified in this study. Results were
computed using the PolyPhen-2 interface for UCSC MultiZ46Way GRCh37/
hg19 and the default Clustalx color coding: conserved A, C, F, H, I, L, M, V,
W, Y or P residues are coloured blue, while conserved S or T residues are in
green. Conserved positively charged residues and negatively charged
residues are coloured red and magenta, respectively. Exact details can be
found in the ClustalX manual (Thompson et al., 1997).
Additional file 3: Pedigree of an ARSACS patient with a second
late-onset dominant cerebellar ataxia segregating in the pedigree.
The family history of index patient #2 (arrow) was positive for a three-
generation late-onset (>30 years), slowly progressive, purely cerebellar
autosomal-dominant ataxia. This led to a time- and cost-extensive work-
up of dominant ataxia genes also in the index patient herself. After these
dominant genes were all negative, also recessive genes were screened,
leading to the identification of two pathogenic SACS variants (p. Arg728*;
p.Phe4352Leufs*11), which were not observed in her affected relatives
(WT= wild type). This observation illustrates that two different hereditary
ataxias should be considered in pedigrees where the ataxia features differ
strongly between pedigree members, e.g. early onset (in the index
patient) vs. late onset (in her relatives), or multisystemic (in the index
patient) vs. purely cerebellar (in her relatives). A timely consideration of
this fact might help to find a correct diagnosis in a more timely manner
and save resources.
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